Trian Fund Management has turned up the heat on Solventum's leadership, publicly arguing that the medical-supplies company's top brass are effectively running the show from out of state while flying into its Eagan campus. The clash ties together very local questions about a new research hub and state incentives with a broader shareholder fight over executive pay and performance.
Most or all of Solventum's senior team, including CEO Bryan Hanson, live outside Minnesota, with Hanson based in Florida. Trian says the C-suite is "effectively remote" and is urging executives to stop commuting to work by private aircraft, according to the Star Tribune. The criticism comes on the heels of Solventum's April 2024 spin from 3M, at a time when investors are still sizing up the company's early performance as a standalone business.
What Trian Is Pushing For
In an April 30 open letter and slide deck, Trian, which says it beneficially owns nearly 5% of Solventum's stock, accused management of prioritizing executive compensation over shareholder value. The firm says the CEO has been paid "more than $80 million in just over two years" and is pressing for immediate cost cuts, a streamlined portfolio and buybacks that are put at the front of the capital-allocation line. Trian Fund Management laid out its case in a detailed public presentation to fellow shareholders.
Local Stakes: The Eagan Hub And State Incentives
Even as this governance brawl unfolds, Solventum has been expanding its Minnesota footprint. The company opened a roughly $200 million Eagan innovation hub this spring, a 250,000-square-foot facility that Solventum says will house research, labs and a pilot factory. Solventum and local reporting note that the project was backed by about $13 million in state development funding and is expected to bring hundreds to more than a thousand high-wage jobs to the region. Finance & Commerce
Shareholders Split On Pay
At Solventum's annual meeting, shareholders approved the advisory say-on-pay vote, but with notable pushback: 105,240,522 votes were cast in favor and 36,603,358 against, according to Solventum's Form 8-K filed with the SEC. That roughly 74% support level sits well below long-term market averages for say-on-pay, which studies from governance advisers like Semler Brossy have pegged in the low 90% range in recent proxy seasons.
Analysts Weigh In On What Comes Next
Wall Street analysts and activists say the public pressure could speed up exactly the kinds of moves Trian is calling for. Some research coverage that began in mid May has already flagged potential divestitures or spin-offs for non-core units such as Health Information Systems and Dental Solutions. Stock Analysis Trian has warned it is prepared to escalate if the board does not respond, while Solventum says it is executing a multi-phase transformation and remains in active dialogue with investors.
For Eagan, where local officials recently cut the ribbon on the new hub, the fight raises a very practical question: will all that investment and those state incentives translate into a day-to-day executive presence on the ground. The coming weeks will test whether Solventum's board tries to square an increasingly remote C-suite with the local commitments the company has already made.
